STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Clinical trials for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE trials appear
Sign up with your email to follow new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for chinese transplant patients: ruxolitinib targets severe immune reaction
Disease control Recruiting nowThis study tests the drug ruxolitinib in Chinese patients aged 12 and older who have a serious immune reaction called acute graft-versus-host disease (aGvHD) after a stem cell transplant, and whose condition did not improve with steroids. The goal is to see if ruxolitinib can con…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Ancient heat therapy takes on transplant complication
Symptom relief Recruiting nowThis study tests whether moxibustion, a traditional Chinese medicine technique that burns herbs near the skin, can help people with severe graft-versus-host disease (GVHD) after a stem cell transplant. About 42 patients who have not responded to steroids will receive standard sec…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Symptom relief
Last updated May 12, 2026 13:44 UTC